

H K E C L E H K L
C C C C C C C C C C C C
C C C C C C C C C C C C
C C C C C C C C C C C C



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(C C C C C C C C)
(Stock Code: 02196)

2013 THIRD QUARTERLY REPORT

T R 13.09(2) R 13.10B R G
L S T S E H K L I I
P P I A S F O (C 571 L H
K)

T 2013 S F P I (G) C .
L * ("Company", b "Group"). T
PRC A S B E
b

B O B
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
C C

S P R C
30 O b 2013

A C F ;
G G C G C K L
C H C H J D L A D

* F C C

Assets: 10,251,236.77

Unit: RMB

Items	The Reporting Period (Jul - Sep)	From the beginning of the year to the end of the Reporting Period	Description
G	10,251,236.77	596,825,644.44	
G	2,878,850.90	13,168,079.40	
G			

The Top 10 unrestricted shareholders of tradable shares

Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
S F H T (G) C., L.	920,641,314	RMB
HKSCC NOMINEES LIMITED ()	335,255,500	O
C L I C., L. D P D — 005L — FH002 S	37,868,964	RMB
C C B — H A H L S S I m F	32,188,808	RMB
I C B C — H T F C L F S	21,318,308	RMB
I C B C — J S G / II b S	19,120,000	RMB
C M B C., L. — E B B D S A S	18,110,252	RMB
N S S F 104	16,599,805	RMB
B C — P H C 50 O S I m F	10,199,839	RMB
B C — A S S I m F	10,000,000	RMB
<p>D</p>	<p>T I C B C — H T F C L F S S I m F C B C — J S G / II b S S I m F L ; T B C — P H C 50 O S I m F F B C — A S C C., L. ; T b B C C B — H A H L S S I m F B C — A S T b H A F M C., L. ; T N S I m F 104 B C — P H C 50 O S I m F b P F M C., L. ; T C 104 3() P J S G -25.72160890</p>	<p>IL</p>

§3 SIGNIFICANT EVENTS

3.1 Significant events in the reporting period: The company's total assets decreased by 50% compared to the beginning of the year, mainly due to the decrease in cash and cash equivalents.

√ A - N - A - b1 - b2 - b3 - b4 - b5 - b6 - b7 - b8 - b9 - b10 - b11 - b12 - b13 - b14 - b15 - b16 - b17 - b18 - b19 - b20 - b21 - b22 - b23 - b24 - b25 - b26 - b27 - b28 - b29 - b30 - b31 - b32 - b33 - b34 - b35 - b36 - b37 - b38 - b39 - b40 - b41 - b42 - b43 - b44 - b45 - b46 - b47 - b48 - b49 - b50 - b51 - b52 - b53 - b54 - b55 - b56 - b57 - b58 - b59 - b60 - b61 - b62 - b63 - b64 - b65 - b66 - b67 - b68 - b69 - b70 - b71 - b72 - b73 - b74 - b75 - b76 - b77 - b78 - b79 - b80 - b81 - b82 - b83 - b84 - b85 - b86 - b87 - b88 - b89 - b90 - b91 - b92 - b93 - b94 - b95 - b96 - b97 - b98 - b99 - b100

Unit: RMB

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Cash and cash equivalents	2,485,783,000.50	4,972,524,758.70	-50%	Mainly due to the decrease in cash and cash equivalents in 2013.
Trade receivables	1,316,781,579.78	907,307,576.06	45%	Mainly due to the increase in trade receivables in 2013.
Inventory	7,615,057.77	17,674,707.55	-57%	Mainly due to the decrease in inventory in 2013.
Intangible assets	2,368,367,750.12	1,752,799,860.87	35%	Mainly due to the increase in intangible assets in 2013.
Development expenditures	42,946,124.18	29,475,413.33	46%	Mainly due to the increase in R&D expenditures in 2013.
Goodwill	2,710,407,586.05	1,661,770,763.96	63%	Mainly due to the increase in goodwill in 2013.
Other non-current assets	236,069,350.21	100,654,101.39	135%	Mainly due to the increase in other non-current assets in 2013.
Deferred tax assets	72,033,067.63	31,482,514.80	129%	Mainly due to the increase in deferred tax assets in 2013.
Share-based payments	1,199,559,074.08	519,422,250.00	131%	Mainly due to the increase in share-based payments in 2013.
Derivative financial assets	12,240,519.57	4,725,748.28	159%	Mainly due to the increase in derivative financial assets in 2013.
Other non-current liabilities	33,196,473.53	526,384,431.15	-94%	Mainly due to the decrease in other non-current liabilities in 2013.

Income Statement				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Operating Profit	7,070,780,938.31	5,387,845,935.96	31%	Mainly due to the increase in operating profit in 2013.
Operating Loss	3,957,631,876.59	3,005,217,397.09	32%	Mainly due to the increase in operating loss in 2013.
Gain/(Loss) from disposal of subsidiaries	39,511,717.28	-14,636,854.56	N/A	Mainly due to the gain from disposal of subsidiaries in 2013.
Income tax expense	313,206,671.22	202,061,631.73	55%	Mainly due to the increase in income tax expense in 2013.
Net Profit	72,257,721.95	33,558,889.22	115%	Mainly due to the increase in net profit in 2013.
Other comprehensive income	285,252,496.15	-436,322,994.17	N/A	Mainly due to the increase in other comprehensive income in 2013.

Statement of Cash Flow				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Net Increase/Decrease in Cash and Cash Equivalents	-1,757,461,995.58	-368,977,652.38	376%	Mainly due to the increase in net increase/decrease in cash and cash equivalents in 2013.

3.2 A. A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P. Q. R. S. T. U. V. W. X. Y. Z. AA. AB. AC. AD. AE. AF. AG. AH. AI. AJ. AK. AL. AM. AN. AO. AP. AQ. AR. AS. AT. AU. AV. AW. AX. AY. AZ. BA. BB. BC. BD. BE. BF. BG. BH. BI. BJ. BK. BL. BM. BN. BO. BP. BQ. BR. BS. BT. BU. BV. BW. BX. BY. BZ. CA. CB. CC. CD. CE. CF. CG. CH. CI. CJ. CK. CL. CM. CN. CO. CP. CQ. CR. CS. CT. CU. CV. CW. CX. CY. CZ. DA. DB. DC. DD. DE. DF. DG. DH. DI. DJ. DK. DL. DM. DN. DO. DP. DQ. DR. DS. DT. DU. DV. DW. DX. DY. DZ. EA. EB. EC. ED. EE. EF. EG. EH. EI. EJ. EK. EL. EM. EN. EO. EP. EQ. ER. ES. ET. EU. EV. EW. EX. EY. EZ. FA. FB. FC. FD. FE. FF. FG. FH. FI. FJ. FK. FL. FM. FN. FO. FP. FQ. FR. FS. FT. FU. FV. FW. FX. FY. FZ. GA. GB. GC. GD. GE. GF. GH. GI. GJ. GK. GL. GM. GN. GO. GP. GQ. GR. GS. GT. GU. GV. GW. GX. GY. GZ. HA. HB. HC. HD. HE. HF. HG. HH. HI. HJ. HK. HL. HM. HN. HO. HP. HQ. HR. HS. HT. HU. HV. HW. HX. HY. HZ. IA. IB. IC. ID. IE. IF. IG. IH. II. IJ. IK. IL. IM. IN. IO. IP. IQ. IR. IS. IT. IU. IV. IW. IX. IY. IZ. JA. JB. JC. JD. JE. JF. JG. JH. JI. JJ. JK. JL. JM. JN. JO. JP. JQ. JR. JS. JT. JU. JV. JW. JX. JY. JZ. KA. KB. KC. KD. KE. KF. KH. KI. KJ. KK. KL. KM. KN. KO. KP. KQ. KR. KS. KT. KU. KV. KW. KX. KY. KZ. LA. LB. LC. LD. LE. LF. LH. LI. LJ. LK. LL. LM. LN. LO. LP. LQ. LR. LS. LT. LU. LV. LW. LX. LY. LZ. MA. MB. MC. MD. ME. MF. MH. MI. MJ. MK. ML. MN. MO. MP. MQ. MR. MS. MT. MU. MV. MW. MX. MY. MZ. NA. NB. NC. ND. NE. NF. NH. NI. NJ. NK. NL. NM. NO. NP. NQ. NR. NS. NT. NU. NV. NW. NX. NY. NZ. OA. OB. OC. OD. OE. OF. OH. OI. OJ. OK. OL. OM. ON. OO. OP. OQ. OR. OS. OT. OU. OV. OW. OX. OY. OZ. PA. PB. PC. PD. PE. PF. PH. PI. PJ. PK. PL. PM. PN. PO. PP. PQ. PR. PS. PT. PU. PV. PW. PX. PY. PZ. QA. QB. QC. QD. QE. QF. QH. QI. QJ. QK. QL. QM. QN. QO. QP. QQ. QR. QS. QT. QU. QV. QW. QX. QY. QZ. RA. RB. RC. RD. RE. RF. RH. RI. RJ. RK. RL. RM. RN. RO. RP. RQ. RR. RS. RT. RU. RV. RW. RX. RY. RZ. SA. SB. SC. SD. SE. SF. SH. SI. SJ. SK. SL. SM. SN. SO. SP. SQ. SR. SS. ST. SU. SV. SW. SX. SY. SZ. TA. TB. TC. TD. TE. TF. TH. TI. TJ. TK. TL. TM. TN. TO. TP. TQ. TR. TS. TT. TU. TV. TW. TX. TY. TZ. UA. UB. UC. UD. UE. UF. UH. UI. UJ. UK. UL. UM. UN. UO. UP. UQ. UR. US. UT. UY. UZ. VA. VB. VC. VD. VE. VF. VH. VI. VJ. VK. VL. VM. VN. VO. VP. VQ. VR. VS. VT. VU. VV. VW. VX. VY. VZ. WA. WB. WC. WD. WE. WF. WH. WI. WJ. WK. WL. WM. WN. WO. WP. WQ. WR. WS. WT. WU. WV. WW. WX. WY. WZ. XA. XB. XC. XD. XE. XF. XH. XI. XJ. XK. XL. XM. XN. XO. XP. XQ. XR. XS. XT. XU. XV. XW. XX. XY. XZ. YA. YB. YC. YD. YE. YF. YH. YI. YJ. YK. YL. YM. YN. YO. YP. YQ. YR. YS. YT. YU. YV. YW. YX. YZ. ZA. ZB. ZC. ZD. ZE. ZF. ZH. ZI. ZJ. ZK. ZL. ZM. ZN. ZO. ZP. ZQ. ZR. ZS. ZT. ZU. ZV. ZW. ZX. ZY. ZZ.

§4 APPENDICES

4.1

Consolidated balance sheet

30 2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB Ten thousand

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash	2,485,783,000.50	4,972,524,758.70
Short-term investments		
Loans		
Financial assets measured at fair value	258,756,754.96	224,834,307.14
Receivables	293,416,923.81	306,710,161.00
Transferable financial assets	1,316,781,579.78	907,307,576.06
Prepaid expenses	279,681,295.65	239,307,192.55
Prepaid insurance		
Reservable assets		
Reservable financial assets		
Intangible assets	7,615,057.77	17,674,707.55
Derivatives	15,697,156.84	12,298,837.25
Other current assets	467,158,390.71	423,080,420.35
Prepaid income tax		
Income tax receivable	1,629,432,467.70	1,273,438,729.51
Non-current assets:		
Long-term investments		
Available-for-sale financial assets	1,665,410,046.04	1,454,122,878.62
Fixed assets		
Long-term equity investments		
Long-term debt investments	9,668,859,344.13	8,593,169,673.95
Intangible assets		
Financial assets measured at fair value	2,987,437,844.46	2,595,295,851.85
Other non-current assets	1,055,727,109.86	881,963,019.23
Liabilities		
Current liabilities:		
Short-term debt		
Accounts payable		
Prepaid expenses		
Other current liabilities		
Non-current liabilities:		
Long-term debt		
Other non-current liabilities		
Equity		
Capital		
Reserves		
Minority interest		
Other equity		

Consolidated balance sheet (Continued)

30

2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
P	2,240,462,364.00	2,240,462,364.00
C	4,396,998,107.25	4,287,287,930.01
L		
S		
St	1,338,476,598.49	1,338,476,598.49
G		
	6,621,610,997.36	5,703,028,462.15
F	-4,289,492.31	-10,462,767.38
T	14,593,258,574.79	13,558,792,587.27
M	1,889,445,595.04	1,745,855,848.86
T	16,482,704,169.83	15,304,648,436.13
T	27,589,580,696.34	25,507,140,466.01

L, R
C, m : C, Q

C, F, O
H, J

D, A
D, m : J

Balance sheet of the Parent Company

30

2013

Parent Company: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB Tenthousand Yuan

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash	967,810,425.06	2,804,108,583.37
Financial assets		
Receivables		
Prepaid expenses		
Inventory	112,185,785.22	98,972,778.68
Due from related parties	24,240,000.00	
Other receivables	1,207,151,982.57	941,562,545.17
Intangible assets	517,042.01	516,409.53
Non-current receivables		
Other non-current assets	280,000,000.00	250,000,000.00
Total	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
Available-for-sale financial assets		
Long-term equity investments		
Long-term receivables	5,471,340,934.74	4,173,763,622.82
Intangible assets		
Fixed assets	20,153,012.47	20,815,349.96
Construction in progress		
Prepaid expenses		
Due from related parties		
Other non-current assets		
Intangible assets	3,215,662.67	3,496,198.41
Due from related parties		
Goodwill		
Long-term equity investments		
Due from related parties		
Other non-current assets	4,470,831,299.40	4,035,133,683.09
Total	9,965,540,909.28	8,233,208,854.28
Total	12,557,446,144.14	12,328,369,171.03

Balance sheet of the Parent Company (Continued)

30

2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
S		
F		
B		
T		
R		
/	26,138,331.81	29,108,232.08
T	16,833,088.84	5,188,721.77
I	155,509,208.37	152,405,396.96
D		
O	554,584,851.12	46,800,203.98
N	360,000,000.00	355,000,000.00
O	499,375,000.00	499,375,000.00
T	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
L	125,000,000.00	165,000,000.00
B	4,070,832,033.25	4,063,347,254.54
L		
S		
A		
D		
O	2,275,000.00	2,500,000.00
T	4,198,107,033.25	4,230,847,254.54
T	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):		
P	2,240,462,364.00	2,240,462,364.00
C	3,754,014,307.53	3,755,009,519.04
L		
S		
S	305,635,420.68	305,635,420.68
G		
	946,161,538.54	708,537,057.98
T	7,246,273,630.75	7,009,644,361.70
T	12,557,446,144.14	12,328,369,171.03

L, R, C, m, Q

C, F, O, H, J

D, A, D, J

Consolidated Income Statement

J € — 2013

Parent Company: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB Tenthousand Yuan

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Total	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income before income tax	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income tax expense				
Financial expenses				
Financial income				
II. Total	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
Income before income tax	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
Income tax expense				
Financial expenses				
Financial income				
Provision for doubtful accounts				
Change in fair value of financial assets				
Net impairment loss of financial assets				
Provision for doubtful accounts				
Amortization of intangible assets				
Depreciation of property, plant and equipment	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
Share of profit of subsidiaries	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
Share of profit of associates	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
Financial income	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
Amortization of intangible assets	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Provision for doubtful accounts (“-”)	-548,949.75	-4,627,534.57	39,511,717.28	-14,636,854.56
Income tax expense (“-”)	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
Income before income tax	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
Financial income (“-”)				
III. Operating profit (“-”)	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Provision for doubtful accounts	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
Loss from non-current assets disposal	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
Income before income tax	260,198.27	-243,201.72	979,886.77	946,040.98

Income Statement of the Parent Company

J € — 2013

Parent Company: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB T

Items	Current Amount (Jul - Sep)	Amount of the Last Period (Jul - Sep)	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
I. Operating Income				
Operating Revenue				
Operating Expenses				
Sales Expenses				
Administrative Expenses	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
Financial Expenses	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
Asset Impairment Losses				
Provision for Doubtful Accounts				
Income Tax Expenses ("—")	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
Income Tax Expenses ("—")	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Operating Loss ("—")	-34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
Provision for Non-current Assets Impairment	76,900.00	234,093.38	236,049.11	734,093.38
Loss on Disposal of Non-current Assets		-570,000.00	2,514,544.42	860,000.00
Income Tax Expenses			5,725.77	
III. Total Profit ("—")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Income Tax Expenses				
IV. Net Profit ("—")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Earnings				
(1) Basic Earnings				
(2) Diluted Earnings				
Other Comprehensive Income			51,779.40	27,699,470.25
Total Profit	-34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

Prepared by: CFO

Chief Financial Officer: H. J.

Director: D. J.

Consolidated Statement of Cash Flow (Continued)

J 6 -

2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
II. Cash flow generated from investing activities (Continued):		
C	711,664,658.89	839,693,736.40
C	251,949,461.45	734,761,521.45
N		
N	2,011,879,515.78	
O	100,020,349.23	9,072,797.31
S b	3,075,513,985.35	1,583,528,055.16
N	-1,757,461,995.58	-368,977,652.38
III. Cash flow generated from financing activities:		
C	2,088,710.98	761,199.00
I	2,088,710.98	761,199.00
C	1,302,361,982.24	1,022,152,808.76
C		1,486,950,000.00
O	329,448,475.13	262,541,891.46
S b	1,633,899,168.35	2,772,405,899.22
C	1,221,891,677.53	2,628,044,486.20
C	950,844,046.86	601,916,917.03
I	702,264,204.84	366,813,171.49
O	48,488,630.70	101,408,014.93
S b	2,221,224,355.09	3,331,369,418.16
N	-587,325,186.74	-558,963,518.94
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-25,426,268.76	-4,569,909.53
V. Net increase of cash and cash equivalents	-1,902,809,425.34	-517,020,589.16
P: O	4,171,574,742.12	2,428,219,484.36
VI. Closing balance of cash and cash equivalents	2,268,765,316.78	1,911,198,895.20

L, R, C, Q

C, F, O, H, J

D, A, J

Statement of Cash Flow of the Parent Company (Continued)

J 6 -

2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
III. Cash flow generated from financing activities:		
C		
C	255,115,078.77	
C		1,486,950,000.00
O	1,904,031,173.98	4,295,169,165.49
S	2,159,146,252.75	5,782,119,165.49
C	790,115,078.77	454,000,000.00
C	674,744,025.09	302,177,196.32
O	2,109,471,293.35	5,478,222,986.00
S	3,574,330,397.21	6,234,400,182.32
N	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
P	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

L. R. C. m. | R. C. Q.

C. F. O. | H. J.

D. A. | D. J.